Emergent BioSolutions to participate in investor conferences.

Emergent BioSolutions' senior management team will participate in two investor conferences: Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and HCW 27th Annual Global Investment Conference on September 9, 2025. The conferences will be webcast, and one-on-one meetings can be requested through conference representatives. Emergent BioSolutions' mission is to protect and save lives by delivering protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.

Emergent BioSolutions Inc. (NYSE: EBS) has announced its participation in two major investor conferences in September 2025. The company will present at the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, at 3:00 PM ET, and at the HCW 27th Annual Global Investment Conference on September 9, 2025, at 1:30 PM ET. Senior management will be available for one-on-one meetings at both events, with presentations and replays accessible through the Investors section of Emergent's website [1].

Emergent BioSolutions' mission is to protect and save lives by delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies. The company has been at work preparing those entrusted with protecting public health for over 25 years [1].

In addition to its upcoming conference participation, Emergent BioSolutions has partnered with Voices for Awareness and Facing Fentanyl Now to support National Fentanyl Prevention and Awareness Day™ on August 21, 2025. The initiative includes high-visibility billboards in Times Square, NYC, to raise awareness about fentanyl risks and reduce stigma around opioid poisonings [2].

The company's commitment to public health extends to its Ready to Rescue initiative, which focuses on combating misinformation surrounding opioid poisonings and empowering the public to make socially responsible decisions to carry over-the-counter naloxone products like NARCAN® Nasal Spray 4 mg and prescription KLOXXADO® Nasal Spray 8 mg [3].

For more information about Emergent BioSolutions, investors can visit the company's website and follow its social media profiles on LinkedIn, X, Instagram, Apple Podcasts, and Spotify.

References:
[1] https://www.stocktitan.net/news/EBS/emergent-bio-solutions-to-participate-in-upcoming-investor-l7twd6jffv6l.html
[2] https://www.ainvest.com/news/hcw-biologics-shares-fall-2-70-premarket-announcing-generation-immunotherapeutics-cancer-treatment-2508/
[3] https://www.stocktitan.net/news/EBS/emergent-bio-solutions-supports-voices-for-awareness-and-facing-zq8fteqwwtkg.html